A Phase 2a Study of Ultratrace Iobenguane I 131 [iodine I 131 metaiodobenzylguanidine] in Patients With Relapsed/Refractory High-Risk Neuroblastoma.

Trial Profile

A Phase 2a Study of Ultratrace Iobenguane I 131 [iodine I 131 metaiodobenzylguanidine] in Patients With Relapsed/Refractory High-Risk Neuroblastoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Iobenguane (Primary)
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Aug 2012 Actual end date Nov 2010 added as reported by ClinicalTrials.gov.
    • 07 Oct 2010 Planned end date changed from 1 Oct 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 23 Jun 2010 Status changed from recruiting to completed, according to a Molecular Insight Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top